The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - MSD; Roche
Research Funding - Agenus; Roche
Travel, Accommodations, Expenses - Agenus; MSD
Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Eutilex; Indivumed; LG Chem; MSD Oncology; Sanofi
Speakers' Bureau - Amgen; BMS/Ono; Eisai; Lilly; MSD Oncology
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Bayer; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Lilly; medpacto; MSD Oncology; Roche/Genentech; Sillajen
 
Wilson H. Miller
Honoraria - Amgen; Bristol Myers Squibb Foundation; EMD Serono; GlaxoSmithKline; Merck; Mylan; Novartis; Roche; Sanofi; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; EMD Serono; GlaxoSmithKline; Merck; Mylan; Novartis; Roche; Sanofi
Research Funding - Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Canada Research Society (Inst); Canadian Cancer Society Research Institute (CCSRI) (Inst); Canadian Institutes of Health Research (CIHR) (Inst); Esperas Pharma (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); MethylGene (Inst); Mimic Technologies (Inst); Novartis (Inst); Ocellaris Pharma (Inst); Pfizer (Inst); Roche (Inst); Samuel Waxman Cancer Research Foundation (Inst); Sanofi (Inst); TERRY FOX RESEARCH INSTITUTE (Inst)
 
María José de Miguel
No Relationships to Disclose
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; GlaxoSmithKline; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
 
Iwona Lugowska
No Relationships to Disclose
 
Martin Wermke
Honoraria - Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cellex GmbH; GEMoaB; Immatics; ISA Pharmaceuticals; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; GEMoaB; Pfizer; Roche
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; Merck Serono; MSD; Ono Pharmaceutical; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Research Funding - CMIC (Inst); CMIC (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Syneos Health (Inst)
 
Todd Michael Bauer
Employment - Tennessee Oncology
Consulting or Advisory Role - Bayer; Lilly; Pfizer; Sanofi
Speakers' Bureau - Bayer; Lilly
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Immunogen (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); MabVax (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
John Palcza
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Marya F. Chaney
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Konstantin Dobrenkov
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Elena Garralda
Consulting or Advisory Role - Alkermes; Anaveon; Boehringer Ingelheim; Bristol-Myers Squibb; Ellipses Pharma; F-Star Therapeutics; Hengrui Therapeutics; Janssen; MAB Discovery; NeoMed; Roche; Seagen; Thermo Fisher Scientific
Speakers' Bureau - Lilly; MSD; Novartis; Roche; Thermo Fisher Scientific
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Other Relationship - Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); BioNTech (Inst); Catalym (Inst); CytomX Therapeutics (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Ribon Therapeutics (Inst); Roche (Inst); Seagen (Inst); Sotio (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst)